Impact of Consuming Plant Sterols on Endothelial Function and Blood Pressure

August 31, 2021 updated by: Jung Eun Kim, National University of Singapore

Impact of Co-consuming a Plant Sterols-enriched Food Product With a Healthy Eating Pattern Diet on Endothelial Function and Blood Pressure Management in Individuals With Metabolic Syndrome

The purpose of the research is to assess the impact of co-consuming plant sterols-enriched food product as part of a healthy eating pattern diet on endothelial function (brachial artery FMD, vasodilation-related and vasoconstriction-related biomarkers) and blood pressure management (24-hour ambulatory and classic blood pressure) in Singapore individuals with MetS.

Study Overview

Detailed Description

This is a 13-wk double-blinded, randomized, crossover study design. Following a 1-wk pre-intervention baseline period, subjects will be randomly assigned to follow a healthy eating pattern diet either contain 2.0 g free plant sterols equivalent of their palmityl esters (Plant Sterol Diet) or do not contain plant sterols (Control Diet) for 4 weeks. After a 4-week dietary 'washout' period, they will consume the alternative diet for 4 weeks. The random assignment will be done with SAS 9.4 software. Body size measurement, dietary assessment, brachial artery FMD and blood pressure measurements, and fasting-state blood collection will be conducted at week 1, 5, 9, and 13, which correspond to before and during the last 1 week of the two 4-week intervention periods.

During study week 1 and weeks 6-9, all subjects will consume their habitual, unrestricted self-chosen diets. During study weeks 2-5 and 10-13, all subject will follow a healthy eating pattern diet, referred to as the "My Healthy Plate" designed by HPB. Each subject's energy requirement will be estimated using sex-specific equations and Recommended Dietary Allowances for healthy Singaporean. One-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff to achieve a healthy eating pattern diet. Compliance with the plant sterols consumption will be promoted by frequent online and in-person contact.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Singapore, Singapore, 117543
        • National University of Singapore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Ability to give an informed consent;
  2. Age>35 years old;
  3. Meet any 3 of the 5 following NCEP-ATP III MetS criteria (waist circumference > 90 cm (male), > 80 cm (female); fasting glucose concentration ≥ 100 mg/dL or on medication; triglyceride ≥ 150 mg/dL or on medication; high density lipoprotein cholesterol (HDL) < 40 mg/dL (male), < 50 mg/dL (female); systolic or diastolic blood pressure > 130/80 mmHg or on medication);
  4. Weight change < 3kg in the past 3 months;
  5. No exercising vigorously over the past 3 months;
  6. No allergy to plant sterols; no acute illness; not smoking;
  7. No drinking more than 2 alcoholic drinks per day;
  8. No pregnant, lactating, or planning pregnancy in the next 6 months.

Exclusion Criteria:

  1. Unable to give an informed consent;
  2. Age<35 years old;
  3. Meet less than 3 of following NCEP-ATP III MetS criteria (waist circumference > 90 cm (male), > 80 cm (female); fasting glucose concentration ≥ 100 mg/dL or on medication; triglyceride ≥ 150 mg/dL or on medication; high density lipoprotein cholesterol (HDL) < 40 mg/dL (male), < 50 mg/dL (female); systolic or diastolic blood pressure > 130/80 mmHg or on medication);
  4. Weight change > 3kg in the past 3 months;
  5. Exercise vigorously over the past 3 months;
  6. Allergy to plant sterols; no acute illness; not smoking;
  7. Drinking more than 2 alcoholic drinks per day;
  8. Pregnant, lactate, or plan pregnancy in the next 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Plant sterol with a healthy diet
Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided with specific instructions to consume plant sterols-enriched food (contains 2 g plant sterols).
Consumption a healthy eating pattern diet with a plant sterols-enriched food product
Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
ACTIVE_COMPARATOR: Healthy diet
Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in brachial artery flow-mediated dilation (FMD)
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Brachial artery FMD will be measured by high-frequency and ultrasonographic imaging.
Every 4 weeks (Week 1, week 5, week 9, week 13)
Change in vasodilation and vasoconstriction related biomarkers
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Vasodilation and vasoconstriction related biomarkers contains nitric oxide, endothelial nitric oxide synthase, and endothelin-1. They will be measured using the commercially available ELISA assay kits.
Every 4 weeks (Week 1, week 5, week 9, week 13)
Change in blood pressure
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Classical and 24-hour ambulatory blood pressure: Systolic and diastolic blood pressure and 5-day of 24-hour ambulatory blood pressure will be measured.
Every 4 weeks (Week 1, week 5, week 9, week 13)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in blood lipid-lipoproteins
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Assessing the blood lipid-lipoproteins profile includes the measurements of plasma total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride concentrations.
Every 4 weeks (Week 1, week 5, week 9, week 13)
Change in skin carotenoid status
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Measured using resonance Raman spectroscopy.
Every 4 weeks (Week 1, week 5, week 9, week 13)
Height
Time Frame: Pre-intervention only
Height (cm)
Pre-intervention only
Change in weight
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Weight (kg)
Every 4 weeks (Week 1, week 5, week 9, week 13)
Change in waist circumference
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Waist circumference (cm)
Every 4 weeks (Week 1, week 5, week 9, week 13)
Change in diet
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Dietary assessment, 3-day food record
Every 4 weeks (Week 1, week 5, week 9, week 13)
Change in sleep quality (Pittsburgh sleep quality index questionnaire (PSQI))
Time Frame: Every 4 weeks (Week 1, week 5, week 9, week 13)
Recall based questionnaire assessing sleep habits for the past one month only which includes sleeping timing habits and quality of sleep (Very good, Fairly good, Fairly bad and very bad)
Every 4 weeks (Week 1, week 5, week 9, week 13)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: J Eun Kim, PhD, National University of Singapore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 9, 2019

Primary Completion (ACTUAL)

May 31, 2021

Study Completion (ACTUAL)

May 31, 2021

Study Registration Dates

First Submitted

October 23, 2018

First Submitted That Met QC Criteria

October 25, 2018

First Posted (ACTUAL)

October 29, 2018

Study Record Updates

Last Update Posted (ACTUAL)

September 8, 2021

Last Update Submitted That Met QC Criteria

August 31, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Electronic copies of the data with identifiable participant information will be kept, data will be de-identified prior to be statistical analysis.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on plant sterols

3
Subscribe